Vir Biotechnology, Inc. (VIR)
| Market Cap | 2.08B +161.3% |
| Revenue (ttm) | 302.80M +1,696.0% |
| Net Income | -184.79M |
| EPS | -1.18 |
| Shares Out | 171.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,060,979 |
| Open | 12.90 |
| Previous Close | 13.13 |
| Day's Range | 12.02 - 12.96 |
| 52-Week Range | 5.32 - 14.38 |
| Beta | 1.74 |
| Analysts | Strong Buy |
| Price Target | 23.38 (+92.9%) |
| Earnings Date | Nov 4, 2026 |
About VIR
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting va... [Read more]
Financial Performance
In 2025, Vir Biotechnology's revenue was $68.56 million, a decrease of -7.61% compared to the previous year's $74.21 million. Losses were -$437.99 million, -16.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $23.38, which is an increase of 92.90% from the latest price.
News
Vir Biotechnology 15M share Spot Secondary priced at $10.00
Leerink, Morgan Stanley and Evercore ISI are acting as joint book running managers for the offering. The deal priced below last closing price of $12.12.
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing...
Vir Biotechnology announces common stock offering, no amount given
Vir Biotechnology (VIR) announced that it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering will be offered…
Vir Biotechnology files automatic mixed securities shelf
16:07 EST Vir Biotechnology (VIR) files automatic mixed securities shelf
Vir Biotechnology Announces Proposed Public Offering
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing...
Vir Biotechnology price target raised to $25 from $22 at Evercore ISI
Evercore ISI raised the firm’s price target on Vir Biotechnology (VIR) to $25 from $22 and keeps an Outperform rating on the shares.
Vir Biotechnology price target raised to $28 from $25 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vir Biotechnology (VIR) to $28 from $25 and keeps an Overweight rating on the shares.
Vir Biotechnology Transcript: Status update
ECLIPSE 1 met its endpoints, with 79% reaching undetectable HDV RNA at week 48 and favorable tolerability. SOLSTICE showed sustained week 96 suppression and early off-treatment responses; ECLIPSE 2/3 data are expected in Q1 2027, ahead of a planned mid-2027 FDA filing.
Vir Biotechnology Slides: Status update
Vir Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Vir Biotechnology Press release: Status update
Vir Biotechnology issued a press release on November 9, 2026, disclosing material business information to investors.
Vir Biotechnology announces new, expanded data from Phase 2 Solstice trial
Vir Biotechnology (VIR) announced new, expanded data from the Phase 2 Solstice trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta, ...
Vir Biotechnology announces Phase 3 Eclipse 1 trial met primary endpoint
Vir Biotechnology (VIR) announced positive topline results from the pivotal Phase 3 Eclipse 1 trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic he...
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran an...
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration ...
Vir Biotechnology price target raised to $17 from $15 at BofA
BofA raised the firm’s price target on Vir Biotechnology (VIR) to $17 from $15 and keeps a Buy rating on the shares.
Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and...
Vir Biotechnology reports Q3 EPS (57c), consensus (75c)
“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnolo...
Vir Biotechnology Earnings Call Transcript: Q3 2026
Phase III HDV readouts are approaching, while VIR-5500 advances toward pivotal development. The Gilead deal adds $90M upfront and extends projected cash runway into H2 2028.
Vir Biotechnology Earnings release: Q3 2026
Vir Biotechnology released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Vir Biotechnology Slides: Q3 2026
Vir Biotechnology has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Vir Biotechnology Quarterly report: Q3 2026
Vir Biotechnology has published its Q3 2026 quarterly earnings report on November 4, 2026.
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are entering...
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies ...
Vir Biotechnology appoints Suzanne Topalian to board of directors
Vir Biotechnology (VIR) announced the appointment of Suzanne Topalian, M.D., to its Board of Directors. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins Univ...
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Top...